Avidocin™ proteins represent a new class of highly targeted antibacterial agents that avoid problems associated with antibiotic use and abuse, and offer opportunities for the prevention and treatment of bacterial diseases and other related issues.
Micacide™ proteins are a new class of therapeutics that mobilize the innate immunity system to efficiently detect and destroy cancerous or virus infected cells including those not effectively addressed by monoclonal antibodies or vaccines.
The DiversiGene™ platform can generate trillions of focused protein variants, thus offering applications for protein engineering and the creation of diversified libraries of protein scaffolds for use in drugs, diagnostics and binding reagents.
AvidBiotics generates non-antibody proteins that specifically target bacteria, viruses or cancer cells for human therapeutic and prophylactic uses, as well as food safety, biodefense, animal husbandry and a host of other potential applications. The basis of AvidBiotics’ technology is specificity – the key to both efficacy and safety in all applications.
South San Francisco, CA (December 15, 2011): AvidBiotics today announced the publication of new findings in PLoS Genetics that could enable genetic Continue»
New Publication Demonstrates Ability of Avidocin™ Proteins to Prevent and Treat E. coli O157 Diarrhea in Animal Study Continue»